PROJECT 4 Many Superfund (SF) chemicals (e.g., PAHs, PCBs, Chlorinated solvents) have been reported to induce reactive oxygen species (ROS) in several cell types. Preliminary studies suggest that most of the ROS induced by SF chemicals originates from the mitochondria and that CCl4-induced cardiomyocyte cell death is partly caused by impaired proteasome activity. The hypothesis that chronic exposure to xenobiotics leads to cellular dysfunction and cell death mainly via mitochondrial oxidative stress (MOS) will be tested. MOS results in excessive production of ROS, increased levels of oxidized mitochondrial proteins, lipids, and DNA, decreased ATP levels, and depolarized mitochondrial membrane potential. Project 4 will further explore whether MOS- related increases in ROS levels affects several cellular pathways, including cellular proteostasis, apoptosis, endoplasmic reticulum (ER) function, and fibrosis. Moreover, preliminary data generated by the research team suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) produce cardiotoxicity by MOS and impaired proteostasis. Since NSAIDs, such as diclofenac, are designed to be bioactive and bioaccumulate in animals, such as fish, it is very likely that these compounds would pose a larger problem than many current SF chemicals in the near future. Among the project aims is to investigate the effects of drug (diclofenac)-SF chemical mixtures. These hypotheses will be tested in cell cultures and chronic animal models. The research team will develop cell-based assays to evaluate the mechanistic basis of xenobiotics effects on MOS and proteostasis (with Core A, Core B and Project 5). This project will evaluate the effects of chronic exposure to xenobiotics on increased MOS, apoptosis, fibrosis, heart damage and associated alterations of plasma oxidized protein levels (with Core A, and B), and develop methods to monitor MOS and impaired proteostasis from chronic exposure to chemicals (with Project 1, 2 and 3 as well as Core A and B). The long term goal of this work is to develop a high-content and medium throughput bioassay to test the potentials of SF chemicals to cause MOS and proteostasis, and obtain a biomarker of MOS associated biological effects for bio-fluid analysis. Overall, this project will investigate a novel hypothesis that current SF chemicals, as well as potential future SF chemicals, cause cellular dysfunction mainly via MOS.

Public Health Relevance

PROJECT 4 This project will investigate the molecular mechanisms of chronic exposure to Superfund (SF) chemicals on mitochondrial oxidative stress (MOS) and proteasome dysfunction, which can lead to fibrosis, cell death and organ damage. The Specific Aims of this project will directly test the novel hypothesis that oxidized proteins and impaired proteasome and immunoproteasome activities may represent a surrogate biomarker for MOS following chronic xenobiotic exposure.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Hazardous Substances Basic Research Grants Program (NIEHS) (P42)
Project #
2P42ES004699-29A1
Application #
9259777
Study Section
Special Emphasis Panel (ZES1)
Project Start
Project End
Budget Start
2017-07-01
Budget End
2018-03-31
Support Year
29
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Taha, Ameer Y; Hennebelle, Marie; Yang, Jun et al. (2018) Regulation of rat plasma and cerebral cortex oxylipin concentrations with increasing levels of dietary linoleic acid. Prostaglandins Leukot Essent Fatty Acids 138:71-80
Hill 3rd, Thomas; Rice, Robert H (2018) DUOX expression in human keratinocytes and bronchial epithelial cells: Influence of vanadate. Toxicol In Vitro 46:257-264
Kodani, Sean D; Wan, Debin; Wagner, Karen M et al. (2018) Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 3:14076-14086
Ren, Qian; Ma, Min; Yang, Jun et al. (2018) Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A 115:E5815-E5823
Pecic, Stevan; Zeki, Amir A; Xu, Xiaoming et al. (2018) Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat 136:90-95
Yamanashi, Haruto; Boeglin, William E; Morisseau, Christophe et al. (2018) Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res 59:684-695
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Napimoga, M H; Rocha, E P; Trindade-da-Silva, C A et al. (2018) Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res 53:743-749
Blöcher, René; Wagner, Karen M; Gopireddy, Raghavender R et al. (2018) Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem 61:3541-3550
Hao, Lei; Kearns, Jamie; Scott, Sheyenne et al. (2018) Indomethacin Enhances Brown Fat Activity. J Pharmacol Exp Ther 365:467-475

Showing the most recent 10 out of 1149 publications